Compare Citius Pharmaceuticals Inc (CTXR) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $31. The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | GSG | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.82 | $34.77 |
52-Week Low | $0.53 | $22.06 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
GSG trades at $30.52, up 3.6% with a bullish technical signal. Moving averages and oscillators support upward momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights institutional shifts toward commodities, aligning with GSG's focus. Key support lies near $30, with resistance at $31.
The outlook remains positive amid commodity-driven market themes, but overbought technicals and reliance on macroeconomic trends pose risks. Upside depends on sustained commodity demand and institutional inflows, while volatility may test near-term support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
